Su Chun-Wen, Lin Chiao-Wen, Yang Wei-En, Yang Shun-Fa
Institute of Medicine, Chung Shan Medical University, Taichung.
Institute of Oral Sciences, Chung Shan Medical University, Taichung.
Ther Adv Med Oncol. 2019 Jul 16;11:1758835919864247. doi: 10.1177/1758835919864247. eCollection 2019.
Tissue inhibitor of metalloproteinase-3 (TIMP-3), a secreted glycoprotein, plays an important role in carcinogenesis. It can bind to many proteinases to suppress their activity and thus protect the extracellular matrix from degradation. TIMP-3 may have many anticancer properties, including apoptosis induction and antiproliferative, antiangiogenic, and antimetastatic activities. This review summarizes the structure, proteinase inhibition ability, genetic and epigenetic regulation, cancer therapy potential, and contribution to cancer development of TIMP-3. Furthermore, in this review we discuss its potential as a biomarker for predicting cancer progression and the current state of drugs that target TIMP-3, either alone or in combination with clinical treatment. In conclusion, TIMP-3 can be a biomarker of cancer and a potential target for cancer therapy. This review article can serve as a basis to understand how to modulate TIMP-3 levels as a drug target of cancers.
金属蛋白酶组织抑制剂-3(TIMP-3)是一种分泌型糖蛋白,在癌症发生过程中发挥重要作用。它能与多种蛋白酶结合以抑制其活性,从而保护细胞外基质不被降解。TIMP-3可能具有多种抗癌特性,包括诱导细胞凋亡以及抗增殖、抗血管生成和抗转移活性。本综述总结了TIMP-3的结构、蛋白酶抑制能力、遗传和表观遗传调控、癌症治疗潜力以及对癌症发展的作用。此外,在本综述中,我们讨论了其作为预测癌症进展的生物标志物的潜力以及单独或与临床治疗联合靶向TIMP-3的药物的现状。总之,TIMP-3可以是癌症的生物标志物和癌症治疗的潜在靶点。这篇综述文章可作为理解如何调节TIMP-3水平作为癌症药物靶点的基础。